Simon Rule, MD from Derriford Hospital, Plymouth, UK discusses current mantle cell lymphoma (MCL) news, including the novel results from clinical trials using ibrutinib and front-line allogeneic transplant. Allogeneic transplant is often not the first-line of treatment due to its toxicity. Instead, treatment for younger patients involves chemotherapy then an autologous stem cell transplant, however patients often still relapse. Prof Rule discusses his clinical trial (NCT00720447) of 25 patients undergoing an allogeneic transplant with a transplant rate of mortality of 8% and progression-free survival 3 years rate of 70%. This suggests that there may be a potential application for patients who are struggling with conventional therapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: Current news in MCL – allogeneic transplants
